About

Angela M. Stover, PhD, is an Associate Professor of Health Policy and Management at the UNC Gillings School of Global Public Health. She co-directs the Implementation Science Methods Unit at the NC Translational and Clinical Sciences Institute (NC TraCS), UNC’s Clinical and Translational Science Award from NIH. With more than 20 years of research experience, her specialization lies in implementing evidence-based practices into clinics and developing patient-reported outcome measures (PROMs). Her research program focuses on identifying gaps in the implementation of PROMs as a standard of care and understanding how these gaps relate to patient and clinic outcomes. Dr. Stover's work has significantly influenced the field, with over 80 peer-reviewed publications cited more than 8,500 times. Her research has been funded by organizations such as NIH, PCORI, AHRQ, Pfizer, and various foundations. She has contributed to evaluating innovative oncology care models, including the use of clinical oncology pharmacists as PROM monitors, and has developed frameworks for implementing PROMs in clinical care. Dr. Stover teaches graduate courses on patient-reported outcomes and implementation science, and actively participates in service activities, including serving on the Board of Directors for the International Society for Quality of Life Research and leading initiatives to advance PROMs in clinical practice.

Research topics

• Medicine
• Internal medicine
• Pathology
• Political Science
• Computer Science
• Medical physics
• Intensive care medicine
• Engineering ethics
• Nursing
• Physical therapy
• Family medicine
• Management science
• Medical education
• Engineering

Selected publications

• Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer

  JAMA · 2022 · 367 citations

  • Medicine
  • Physical therapy
  • Internal medicine

  <h3>Importance</h3> Electronic systems that facilitate patient-reported outcome (PRO) surveys for patients with cancer may detect symptoms early and prompt clinicians to intervene. <h3>Objective</h3> To evaluate whether electronic symptom monitoring during cancer treatment confers benefits on quality-of-life outcomes. <h3>Design, Setting, and Participants</h3> Report of secondary outcomes from the PRO-TECT (Alliance AFT-39) cluster randomized trial in 52 US community oncology practices randomized to electronic symptom monitoring with PRO surveys or usual care. Between October 2017 and March 2020, 1191 adults being treated for metastatic cancer were enrolled, with last follow-up on May 17, 2021. <h3>Interventions</h3> In the PRO group, participants (n = 593) were asked to complete weekly surveys via an internet-based or automated telephone system for up to 1 year. Severe or worsening symptoms triggered care team alerts. The control group (n = 598) received usual care. <h3>Main Outcomes and Measures</h3> The 3 prespecified secondary outcomes were physical function, symptom control, and health-related quality of life (HRQOL) at 3 months, measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30; range, 0-100 points; minimum clinically important difference [MCID], 2-7 for physical function; no MCID defined for symptom control or HRQOL). Results on the primary outcome, overall survival, are not yet available. <h3>Results</h3> Among 52 practices, 1191 patients were included (mean age, 62.2 years; 694 [58.3%] women); 1066 (89.5%) completed 3-month follow-up. Compared with usual care, mean changes on the QLQ-C30 from baseline to 3 months were significantly improved in the PRO group for physical function (PRO, from 74.27 to 75.81 points; control, from 73.54 to 72.61 points; mean difference, 2.47 [95% CI, 0.41-4.53];<i>P</i> = .02), symptom control (PRO, from 77.67 to 80.03 points; control, from 76.75 to 76.55 points; mean difference, 2.56 [95% CI, 0.95-4.17];<i>P</i> = .002), and HRQOL (PRO, from 78.11 to 80.03 points; control, from 77.00 to 76.50 points; mean difference, 2.43 [95% CI, 0.90-3.96];<i>P</i> = .002). Patients in the PRO group had significantly greater odds of experiencing clinically meaningful benefits vs usual care for physical function (7.7% more with improvements of ≥5 points and 6.1% fewer with worsening of ≥5 points; odds ratio [OR], 1.35 [95% CI, 1.08-1.70];<i>P</i> = .009), symptom control (8.6% and 7.5%, respectively; OR, 1.50 [95% CI, 1.15-1.95];<i>P</i> = .003), and HRQOL (8.5% and 4.9%, respectively; OR, 1.41 [95% CI, 1.10-1.81];<i>P</i> = .006). <h3>Conclusions and Relevance</h3> In this report of secondary outcomes from a randomized clinical trial of adults receiving cancer treatment, use of weekly electronic PRO surveys to monitor symptoms, compared with usual care, resulted in statistically significant improvements in physical function, symptom control, and HRQOL at 3 months, with mean improvements of approximately 2.5 points on a 0- to 100-point scale. These findings should be interpreted provisionally pending results of the primary outcome of overall survival. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT03249090

  DOI

• The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

  Annals of Oncology · 2022 · 464 citations

  • Medicine
  • Intensive care medicine
  • Family medicine

  This ESMO Guideline provides key recommendations on the role of PROMs during the care of patients with cancer. It covers the use of PROMs in patients with cancer from the start of active treatment during follow-up and at the end of life. Recommendations are based on available scientific evidence and the authors’ collective expert consensus. Authorship includes a multidisciplinary group of experts from Europe, North America, Asia and Australia.

  DOI

• Improvement Science and Implementation Science in Cancer Care: Identifying Areas of Synergy and Opportunities for Further Integration

  Journal of General Internal Medicine · 2020 · 48 citations

  • Computer Science
  • Political Science
  • Medicine
  DOI

Frequent coauthors

• Ethan Basch

  77 shared

• Antonia V. Bennett

  40 shared

• Bryce B. Reeve

  Duke University

  39 shared

• Doris Howell

  Princess Margaret Cancer Centre

  30 shared

• Jennifer Young Pierce

  University of Alabama at Birmingham

  29 shared

• Gabrielle B. Rocque

  University of Alabama at Birmingham

  29 shared

• Bryan J. Weiner

  23 shared

• Jennifer Jansen

  University of North Carolina at Chapel Hill

  22 shared

Education

• Postdoc

  Cancer Care Quality Training Program

  2017

• PhD, Health Behavior

  University of North Carolina at Chapel Hill

  2015

• MA, Psychology in Education (Psychometrics)

  University of Pittsburgh

  2002

• BA (double major with honors), Psychology and Sociology departments

  Westminster University

  1998

Awards & honors

• Sigma Xi Scientific Research Honor Society Inductee 2025
• Finalist for "Best Paper of the Year" Award 2021, Journal Qu…
• Emerging Leader 2020, International Society for Quality of L…
• UNC Provost Award for Junior Faculty Research 2020
• Chair 2019-2021, International Society for Quality of Life r…

Similar researchers at University of North Carolina at Chapel Hill

• Barry M. Popkinh-170
• Cynthia Bulikh-134
• Doug Perkinsh-115
• Paul Watkinsh-107
• Linda Adairh-106